US2020277666A1PendingUtilityA1
Noninvasive diagnostics by sequencing 5-hydroxymethylated cell-free dna
Est. expiryApr 7, 2036(~9.7 yrs left)· nominal 20-yr term from priority
C12Q 1/6869C12N 15/00C12Q 1/6806C40B 50/04C12Q 2545/101C12Q 2525/191C12Q 1/6886C40B 70/00C12Q 1/6855C12Q 2600/154C40B 40/08C12Q 2563/185
73
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
Provided herein is a method of sequencing hydroxymethyated cell-free DNA. In some embodiments, the method comprises adding an affinity tag to only hydroxymethyated DNA molecules in a sample of cfDNA, enriching for the DNA molecules that are tagged with the affinity tag; and sequencing the enriched DNA molecules.
Claims
exact text as granted — not AI-modifiedWhat is claimed is:
1 . A method for identifying more highly expressed genes in a cell-free nucleic acid sample comprising cell-free DNA, wherein the method comprises:
(a) determining hydroxymethylation profiles for the cell-free DNA in the sample; (b) comparing the hydroxymethylation profiles to identify locations with 5hmC enrichment; and (c) identifying the more highly expressed genes in the sample as those with gene bodies around which 5hmC is enriched.Join the waitlist — get patent alerts
Track US2020277666A1 — get alerts on status changes and closely related new filings.
We store only your email — no account needed. See our privacy policy.